Johnson & Johnson sales rose 5.90 percent. Johnson & Johnson stock sits 5.41 percent below high

Published on 10/26/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings beat by USD 0.05 in the third quarter. Johnson & Johnson stock costs EUR 238.00 on October 26, 2026, up 1.26 percent versus Xetra close.

Sales and valuation in view

Johnson & Johnson reported third-quarter sales of USD 25.40 billion, up 5.90 percent, on October 13, 2026.
Innovative Medicine grew 7.90 percent, while MedTech grew 2.50 percent in the third quarter of 2026.
Johnson & Johnson stock costs EUR 238.00 at Lang & Schwarz on October 26, 2026, up 1.26 percent versus the Xetra close of October 23, 2026.
The company had a USD 640.0 billion market capitalization and a P/E ratio of 40.35 on October 26, 2026.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) reported third-quarter sales of USD 25.40 billion on October 13, 2026, up 5.90 percent from USD 23.99 billion in the same quarter of 2025, according to Johnson & Johnson. At Lang & Schwarz, the stock was trading at EUR 238.00 on October 26, 2026 at 4:35 p.m. CET, up 1.26 percent versus the Xetra close of October 23, 2026 at EUR 235.05.

Innovative Medicine leads growth

The third-quarter sales split favored Innovative Medicine. The segment generated USD 16.76 billion, up 7.90 percent from USD 15.56 billion a year earlier, while MedTech sales reached USD 8.64 billion, up 2.50 percent from USD 8.43 billion, according to the October 13, 2026 release from Johnson & Johnson. The contrast matters because the pharmaceutical business supplied the larger share of quarterly sales and the faster reported growth.

What does the segment split mean?

Innovative Medicine accounted for 65.98 percent of the USD 25.40 billion quarterly total, calculated from the reported segment figures. MedTech contributed 34.02 percent, so a recovery in the slower division would have a smaller immediate effect on group revenue than continued pharmaceutical growth.

Stock remains below its yearly high

On the NYSE, Johnson & Johnson was last at USD 265.86 on October 26, 2026 at 11:40 a.m. EDT. The same quotation placed its 52-week range at USD 184.66 to USD 281.07, leaving the stock 5.41 percent below the high. The intraday US move was plus 0.78 percent, separate from the euro move against the Xetra close.

Valuation and peer comparison

Johnson & Johnson had a market capitalization of USD 640.0 billion, a P/E ratio of 40.35 and a dividend yield of 2.00 percent on October 26, 2026. The valuation is higher than the reported figures alone might suggest, making the earnings path and segment mix central to the stock's market profile.

Comparison with peers

Johnson & Johnson: up 1.26 percent, P/E 40.35, market capitalization USD 640.0 billion.

Merck & Co.: down 2.14 percent, P/E 113.73, market capitalization USD 350.7 billion.

AbbVie: up 0.38 percent, P/E 80.78, market capitalization USD 506.7 billion.

Euro quote and Xetra comparison

Johnson & Johnson stock was trading at EUR 238.00 at Lang & Schwarz on October 26, 2026 at 4:35 p.m. CET, up 1.26 percent versus the Xetra close of October 23, 2026 at EUR 235.05. The euro quotation was above the prior Xetra level while the US listing remained 5.41 percent below its 52-week high. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.